Integrated Analysis of Key Genes and Pathways Involved in Nonalcoholic Steatohepatitis Improvement After Roux-en-Y Gastric Bypass Surgery

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2021 Feb 19

PMID 33603714

Citations 4

Authors

Fu Chen

Yong Zhou

Zhiyuan Wu

Yunze Li

Wenlong Zhou

Yong Wang

Affiliations

Soon will be listed here.

Abstract

Background: As the incidence of nonalcoholic fatty liver disease (NAFLD) increases globally, nonalcoholic steatohepatitis (NASH) has become the second common cause of liver transplantation for liver diseases. Recent evidence shows that Roux-en-Y gastric bypass (RYGB) surgery obviously alleviates NASH. However, the mechanism underlying RYGB induced NASH improvement is still elusive.

Methods: We obtained datasets, including hepatic gene expression data and histologic NASH status, at baseline and 1 year after RYGB surgery. Differentially expressed genes (DEGs) were identified comparing gene expression before and after RYGB surgery in each dataset. Common DEGs were obtained between both datasets and further subjected to functional and pathway enrichment analysis. Protein-protein interaction (PPI) network was constructed, and key modules and hub genes were also identified.

Results: In the present study, GSE106737 and GSE83452 datasets were included. One hundred thirty common DEGs (29 up-regulated and 101 down-regulated) were identified between GSE106737 and GSE83452 datasets. KEGG analysis showed that mineral absorption, IL-17 signaling pathway, osteoclast differentiation, and TNF signaling pathway were significantly enriched. Based on the PPI network, , , , , , , , , , , , , and were identified as hub genes, and three functional modules were also extracted.

Conclusion: This study identifies the global gene expression change in the liver of NASH patients before and after RYGB surgery in a bioinformatic method. Our findings will contribute to the understanding of molecular biological changes underlying NASH improvement after RYGB surgery.

Citing Articles

Silybin A from reprograms lipid metabolism to induce a cell fate-dependent class switch from triglycerides to phospholipids.

Koeberle S, Thurmer M, Su F, Werner M, Grander J, Hofer L Theranostics. 2025; 15(5):2006-2034.

PMID: 39897559 PMC: 11780512. DOI: 10.7150/thno.99562.

Analysis of Common Pathways and Markers From Non-Alcoholic Fatty Liver Disease to Immune-Mediated Diseases.

Gallego-Duran R, Montero-Vallejo R, Maya-Miles D, Lucena A, Martin F, Ampuero J Front Immunol. 2021; 12:667354.

PMID: 34899679 PMC: 8652219. DOI: 10.3389/fimmu.2021.667354.

A novel immune-related genes signature after bariatric surgery is histologically associated with non-alcoholic fatty liver disease.

Song Y, Zhang J, Wang H, Guo D, Yuan C, Liu B Adipocyte. 2021; 10(1):424-434.

PMID: 34506234 PMC: 8437528. DOI: 10.1080/21623945.2021.1970341.

Dynamic co-expression modular network analysis in nonalcoholic fatty liver disease.

Zheng J, Wu H, Zhang Z, Yao S Hereditas. 2021; 158(1):31.

PMID: 34419146 PMC: 8380347. DOI: 10.1186/s41065-021-00196-8.

Gut Microbiome and Metabolites in Patients with NAFLD and after Bariatric Surgery: A Comprehensive Review.

Hoozemans J, De Brauw M, Nieuwdorp M, Gerdes V Metabolites. 2021; 11(6).

PMID: 34072995 PMC: 8227414. DOI: 10.3390/metabo11060353.

References

Caiazzo R, Lassailly G, Leteurtre E, Baud G, Verkindt H, Raverdy V . Roux-en-Y gastric bypass versus adjustable gastric banding to reduce nonalcoholic fatty liver disease: a 5-year controlled longitudinal study. Ann Surg. 2014; 260(5):893-8. DOI: 10.1097/SLA.0000000000000945. View

Younossi Z, Koenig A, Abdelatif D, Fazel Y, Henry L, Wymer M . Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2015; 64(1):73-84. DOI: 10.1002/hep.28431. View

Zimmermann H, Tacke F . Modification of chemokine pathways and immune cell infiltration as a novel therapeutic approach in liver inflammation and fibrosis. Inflamm Allergy Drug Targets. 2011; 10(6):509-36. DOI: 10.2174/187152811798104890. View

Marra F, Tacke F . Roles for chemokines in liver disease. Gastroenterology. 2014; 147(3):577-594.e1. DOI: 10.1053/j.gastro.2014.06.043. View

Wang Y, Cao F, Wang Y, Yu G, Jia B . Silencing of SAA1 inhibits palmitate- or high-fat diet induced insulin resistance through suppression of the NF-κB pathway. Mol Med. 2019; 25(1):17. PMC: 6503374. DOI: 10.1186/s10020-019-0075-4. View

Wu Q, Zhang X, Zhong M, Han H, Liu S, Liu T . Effects of Bariatric Surgery on Serum Bile Acid Composition and Conjugation in a Diabetic Rat Model. Obes Surg. 2016; 26(10):2384-92. DOI: 10.1007/s11695-016-2087-2. View

Dorn C, Engelmann J, Saugspier M, Koch A, Hartmann A, Muller M . Increased expression of c-Jun in nonalcoholic fatty liver disease. Lab Invest. 2014; 94(4):394-408. DOI: 10.1038/labinvest.2014.3. View

Szklarczyk D, Morris J, Cook H, Kuhn M, Wyder S, Simonovic M . The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res. 2016; 45(D1):D362-D368. PMC: 5210637. DOI: 10.1093/nar/gkw937. View

Serhal R, Hilal G, Boutros G, Sidaoui J, Wardi L, Ezzeddine S . Nonalcoholic Steatohepatitis: Involvement of the Telomerase and Proinflammatory Mediators. Biomed Res Int. 2015; 2015:850246. PMC: 4529930. DOI: 10.1155/2015/850246. View

10.

Ponce de Leon-Ballesteros G, Sanchez-Aguilar H, Velazquez-Fernandez D, Nava-Ponce T, Herrera M . Roux-en-Y Gastric Bypass in Patients >60 Years of Age: Morbidity and Short-Term Outcomes. Obes Surg. 2020; 30(12):5033-5040. DOI: 10.1007/s11695-020-04957-8. View

11.

Boutros T, Chevet E, Metrakos P . Mitogen-activated protein (MAP) kinase/MAP kinase phosphatase regulation: roles in cell growth, death, and cancer. Pharmacol Rev. 2008; 60(3):261-310. DOI: 10.1124/pr.107.00106. View

12.

Yuan Z, Zhang X, Wu Y, Zeng Z, She W, Chen S . Serum amyloid A levels in patients with liver diseases. World J Gastroenterol. 2019; 25(43):6440-6450. PMC: 6881510. DOI: 10.3748/wjg.v25.i43.6440. View

13.

Fuest M, Willim K, MacNelly S, Fellner N, Resch G, Blum H . The transcription factor c-Jun protects against sustained hepatic endoplasmic reticulum stress thereby promoting hepatocyte survival. Hepatology. 2011; 55(2):408-18. DOI: 10.1002/hep.24699. View

14.

Halazonetis T, Georgopoulos K, Greenberg M, Leder P . c-Jun dimerizes with itself and with c-Fos, forming complexes of different DNA binding affinities. Cell. 1988; 55(5):917-24. DOI: 10.1016/0092-8674(88)90147-x. View

15.

Lefebvre P, Lalloyer F, Bauge E, Pawlak M, Gheeraert C, Dehondt H . Interspecies NASH disease activity whole-genome profiling identifies a fibrogenic role of PPARα-regulated dermatopontin. JCI Insight. 2017; 2(13). PMC: 5499370. DOI: 10.1172/jci.insight.92264. View

16.

Dai W, Sun Y, Jiang Z, Du K, Xia N, Zhong G . Key genes associated with non-alcoholic fatty liver disease and acute myocardial infarction. Med Sci Monit. 2020; 26:e922492. PMC: 7341693. DOI: 10.12659/MSM.922492. View

17.

Misra S, Nandhini B, Christinajoice S, Kumar S, Prabhakaran S, Palanivelu C . Is Laparoscopic Roux-en-Y Gastric Bypass Still the Gold Standard Procedure for Indians? Mid- to Long-Term Outcomes from a Tertiary Care Center. Obes Surg. 2020; 30(11):4482-4493. DOI: 10.1007/s11695-020-04849-x. View

18.

Yu G, Wang L, Han Y, He Q . clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012; 16(5):284-7. PMC: 3339379. DOI: 10.1089/omi.2011.0118. View

19.

Fan J, Kim S, Wong V . New trends on obesity and NAFLD in Asia. J Hepatol. 2017; 67(4):862-873. DOI: 10.1016/j.jhep.2017.06.003. View

20.

Flach R, Qin H, Zhang L, Bennett A . Loss of mitogen-activated protein kinase phosphatase-1 protects from hepatic steatosis by repression of cell death-inducing DNA fragmentation factor A (DFFA)-like effector C (CIDEC)/fat-specific protein 27. J Biol Chem. 2011; 286(25):22195-202. PMC: 3121364. DOI: 10.1074/jbc.M110.210237. View